The price of Lifecore Biomedical Inc (NASDAQ: LFCR) closed at $5.01 in the last session, down -30.32% from day before closing price of $7.19. In other words, the price has decreased by -$2.18 from its previous closing price. On the day, 2945410 shares were traded.
Ratios:
We take a closer look at LFCR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.39 and its Current Ratio is at 2.56. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 2.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stephens on March 20, 2023, Downgraded its rating to Equal-Weight and sets its target price to $2 from $11 previously.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LFCR now has a Market Capitalization of 147.86M and an Enterprise Value of 241.51M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.08. Its current Enterprise Value per Revenue stands at 2.34 whereas that against EBITDA is -6.53.
Stock Price History:
Over the past 52 weeks, LFCR has reached a high of $11.45, while it has fallen to a 52-week low of $1.80. The 50-Day Moving Average of the stock is 7.43, while the 200-Day Moving Average is calculated to be 7.91.
Shares Statistics:
According to the various share statistics, LFCR traded on average about 124.42K shares per day over the past 3-months and 363.83k shares per day over the past 10 days. A total of 29.51M shares are outstanding, with a floating share count of 29.41M. Insiders hold about 3.00% of the company’s shares, while institutions hold 69.98% stake in the company. Shares short for LFCR as of Feb 29, 2024 were 1.73M with a Short Ratio of 13.94, compared to 1.62M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.88% and a Short% of Float of 6.75%.
Earnings Estimates
The company has 0 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.32. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.42 and -$0.42 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.14, with 1 analysts recommending between -$0.14 and -$0.14.
Revenue Estimates
According to 2 analysts, the current quarter’s revenue is expected to be $24.54M. It ranges from a high estimate of $24.79M to a low estimate of $24.3M. As of the current estimate, Lifecore Biomedical Inc’s year-ago sales were $42.74M, an estimated decrease of -42.60% from the year-ago figure.
A total of 1 analysts have provided revenue estimates for LFCR’s current fiscal year. The highest revenue estimate was $123.63M, while the lowest revenue estimate was $123.63M, resulting in an average revenue estimate of $123.63M. In the same quarter a year ago, actual revenue was $103.27M, up 19.70% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $141.96M in the next fiscal year. The high estimate is $141.96M and the low estimate is $141.96M. The average revenue growth estimate for next year is up 14.80% from the average revenue estimate for this year.
